Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma.

S Kimura1, N Kakazu, J Kuroda

  • 1Division of Hematology, Kyoto Second Red Cross Hospital, Japan.

Annals of Hematology
|June 13, 2001
PubMed
Summary

Blastic natural killer cell leukemia/lymphoma (blastic NKL/L) is a rare cancer. This case study details a patient with blastic NKL/L who achieved long-term remission with acute lymphoblastic leukemia chemotherapy, challenging the typical poor prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

5-HT3 receptor antagonists. 1. New quinoline derivatives.

Journal of medicinal chemistry·1992
Same author

New bronchodilators. II. 3H-imidazo[4,5-c]quinolin-4(5H)-ones.

Chemical & pharmaceutical bulletin·1992
Same author

Site of attachment of mercuribenzoate in crystals of an actin:DNase I complex.

Journal of biochemistry·1992
Same author

Further studies on aspartate aminotransferase of thermophilic methanogens by analysis of general properties, bound cofactors, and subunit structures.

Journal of biochemistry·1992
Same author

Elevated expression of the ornithine decarboxylase gene in human esophageal cancer.

Cancer research·1992
Same author

Experimental chemotherapy for xenograft cell lines of human bile duct and gall bladder cancers in nude mice.

Journal of surgical oncology·1992

Area of Science:

  • Hematology
  • Oncology
  • Immunophenotyping

Background:

  • Blastic natural killer cell leukemia/lymphoma (blastic NKL/L) presents with blastic morphology and a unique immunophenotype, often mimicking acute myeloid or lymphoid leukemia.
  • Systematic identification of clinical, pathological, and cytogenetic features of blastic NKL/L remains limited.
  • Understanding the specific characteristics of blastic NKL/L is crucial for accurate diagnosis and treatment strategies.

Observation:

  • A case of blastic NKL/L is presented with skin lesions, adenopathy, and systemic lymphadenopathy.
  • Tumor cells were immunophenotypically characterized as CD4+, CD56+, and negative for T-cell, B-cell, and myeloid markers.
  • Bone marrow cells exhibited germ-line configurations for T-cell receptor and immunoglobulin heavy chain genes, and no Epstein-Barr virus infection was detected.

Related Experiment Videos

Findings:

  • The patient received combined chemotherapy typically used for acute lymphoblastic leukemia.
  • Despite the generally poor prognosis and chemotherapy resistance associated with blastic NKL/L, the patient achieved and maintained complete remission for over 13 months.
  • Detailed cytogenetic analysis using G-banding and spectral karyotyping revealed a complex karyotype: 45, XY, der(1)t(1;20)(p32;q11.2), der(6)(1pter-->1p32::6p21.1-->6q13::7q11.2-->7qter), der(7)t(7;20)(q11.2;q11.2), t(13;14)(q14;q32), der(13)t(6;13)(p21.1;q14), -20.

Implications:

  • This case suggests that blastic NKL/L may be responsive to chemotherapy regimens typically used for acute lymphoblastic leukemia.
  • The findings challenge the conventional understanding of blastic NKL/L as universally chemotherapy-resistant with a poor prognosis.
  • Further research into novel therapeutic approaches and detailed cytogenetic analysis is warranted for blastic NKL/L management.